Skip to main content

Advertisement

SpringerLink
Log in

Neuropsychiatric Issues in Parkinson’s Disease

  • Movement Disorders (S Fox, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Cognitive and neuropsychiatric symptoms are common in Parkinson’s Disease and may surpass motor symptoms as the major factors impacting patient quality of life. The symptoms may be broadly separated into those associated with the disease process and those that represent adverse effects of treatment. Symptoms attributed to the disease arise from pathologic changes within multiple brain regions and are not restricted to dysfunction in the dopaminergic system. Mood symptoms such as depression, anxiety, and apathy are common and may precede the development of motor symptoms by years, while other neuropsychiatric symptoms such as cognitive impairment, dementia, and psychosis are more common in later stages of the disease. Neuropsychiatric symptoms attributed to treatment include impulse control disorders, pathologic use of dopaminergic medications, and psychosis. This manuscript will review the current understanding of neuropsychiatric symptoms in Parkinson’s Disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord. 2015;30(2):229–37.

    Article  PubMed  Google Scholar 

  2. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord. 2012;27(5):617–26.

    Article  PubMed  Google Scholar 

  3. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis. 2012;46(3):581–9.

    Article  PubMed  Google Scholar 

  4. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23(2):183–9.

    Article  PubMed  Google Scholar 

  5. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol. 2009;201:1–119.

    PubMed  Google Scholar 

  6. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211.

    Article  PubMed  Google Scholar 

  7. Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. Mov Disord. 2014;29(14):1710–9.

    Article  CAS  PubMed  Google Scholar 

  8. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009;66(2):167–72.

    Article  PubMed  Google Scholar 

  9. Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80(9):800–9.

    Article  PubMed  Google Scholar 

  10. Nuti A, Ceravolo R, Piccinni A, et al. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol. 2004;11(5):315–20.

    Article  CAS  PubMed  Google Scholar 

  11. Tan LC. Mood disorders in Parkinson's disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S74–6.

    Article  PubMed  Google Scholar 

  12. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry. 2007;29(5):409–16.

    Article  PubMed  Google Scholar 

  13. Bomasang-Layno E, Fadlon I, Murray AN, et al. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2015;21(8):833–42. This review provides a quantitative meta-analysis of randomized, controlled trials for treatment of depression in PD. It includes evaluation of drug categories, evaluation ofeffect sizes, and critical assessment of the included articles.

    Article  PubMed  Google Scholar 

  14. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850–7.

    Article  PubMed  Google Scholar 

  15. Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry. 2003;18(6):552–4.

    Article  CAS  PubMed  Google Scholar 

  16. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord. 2006;21(8):1119–22.

    Article  PubMed  Google Scholar 

  17. Avila A, Cardona X, Martin-Baranera M, et al. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol. 2003;23(5):509–13.

    Article  CAS  PubMed  Google Scholar 

  18. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229–36. This study demonstrates efficacy of an SSRI and SNRI vs placebo in treating depression in PD.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rios Romenets S. L. Creti, C. Fichten, et al., Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease—a randomized study. Parkinsonism Relat Disord. 2013;19(7):670–5.

    Article  CAS  PubMed  Google Scholar 

  21. Werneck AL, Rosso AL, Vincent MB. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson's disease. Arq Neuropsiquiatr. 2009;67(2B):407–12.

    Article  PubMed  Google Scholar 

  22. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10(4):399–406.

    Article  CAS  PubMed  Google Scholar 

  23. Navan P, Findley LJ, Jeffs JA, et al. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov Disord. 2003;18(11):1324–31.

    Article  PubMed  Google Scholar 

  24. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ondo WG, Shinawi L, Davidson A, et al. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord. 2011;17(3):156–9.

    Article  PubMed  Google Scholar 

  26. Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Med Hypotheses. 2010;75(6):544–6.

    Article  CAS  PubMed  Google Scholar 

  27. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology. 1984;34(8):1092–4.

    Article  CAS  PubMed  Google Scholar 

  28. Zaluska M, Dyduch A. Bupropion in the treatment of depression in Parkinson's disease. Int Psychogeriatr. 2011;23(2):325–7.

    Article  PubMed  Google Scholar 

  29. Grandas F, Lopez-Manzanares L. Bupropion-induced parkinsonism. Mov Disord. 2007;22(12):1830–1.

    Article  PubMed  Google Scholar 

  30. Cheng WC, Liu CM, Hsieh MH, et al. Bupropion-related parkinsonism and dystonia. J Clin Psychopharmacol. 2009;29(6):616–8.

    Article  PubMed  Google Scholar 

  31. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601–7.

    Article  CAS  PubMed  Google Scholar 

  32. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–80.

    Article  CAS  PubMed  Google Scholar 

  33. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S42–80.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ray Chaudhuri K. P. Martinez-Martin, A. Antonini, et al., Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660–5.

    Article  CAS  PubMed  Google Scholar 

  35. Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. Drugs. 2011;71(3):273–86.

    Article  CAS  PubMed  Google Scholar 

  36. Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics. 2014;11(1):78–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Carpenter LL, Milosavljevic N, Schecter JM, et al. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005;66(10):1234–8.

    Article  CAS  PubMed  Google Scholar 

  38. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry. 1989;52(6):724–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol. 2004;55(6):766–73.

    Article  CAS  PubMed  Google Scholar 

  40. Leentjens AF, Dujardin K, Marsh L, et al. Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord. 2011;26(3):484–92.

    Article  PubMed  Google Scholar 

  41. Prediger RD, Matheus FC, Schwarzbold ML, et al. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology. 2012;62(1):115–24.

    Article  CAS  PubMed  Google Scholar 

  42. Rutten S, Ghielen I, Vriend C, et al. Anxiety in Parkinson's disease: Symptom dimensions and overlap with depression and autonomic failure. Parkinsonism Relat Disord. 2015;21(3):189–93.

    Article  PubMed  Google Scholar 

  43. Dissanayaka NN, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord. 2010;25(7):838–45.

    Article  PubMed  Google Scholar 

  44. Couto MI, Monteiro A, Oliveira A, et al. Depression and anxiety following deep brain stimulation in Parkinson's disease: systematic review and meta-analysis. Acta Med Port. 2014;27(3):372–82.

    Article  PubMed  Google Scholar 

  45. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol. 2008;7(7):605–14.

    Article  PubMed  Google Scholar 

  46. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord. 2007;22(6):778–84.

    Article  PubMed  Google Scholar 

  47. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord. 2008;23(13):1889–96.

    Article  PubMed  Google Scholar 

  48. Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015;14(5):518–31.

    Article  PubMed  Google Scholar 

  49. Butterfield LC, Cimino CR, Oelke LE, et al. The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. Neuropsychology. 2010;24(6):721–30.

    Article  PubMed  Google Scholar 

  50. Dujardin K, Sockeel P, Delliaux M, et al. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord. 2009;24(16):2391–7.

    Article  PubMed  Google Scholar 

  51. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. Parkinsonism Relat Disord. 2015;21(6):629–34.

    Article  PubMed  Google Scholar 

  52. Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85(6):668–74.

    Article  PubMed  Google Scholar 

  53. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2002;14(4):461–2.

    Article  PubMed  Google Scholar 

  54. Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: amulticentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11(7):589–96.

    Article  CAS  PubMed  Google Scholar 

  55. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136(Pt 5):1568–77.

    Article  PubMed  Google Scholar 

  56. Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23(7):964–9.

    Article  PubMed  Google Scholar 

  57. Broeders M, Velseboer DC, de Bie R, et al. Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study. J Int Neuropsychol Soc. 2013;19(6):695–708.

    Article  PubMed  Google Scholar 

  58. Goldman JG, Litvan I. Mild cognitive impairment in Parkinson's disease. Minerva Med. 2011;102(6):441–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814–24.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Pigott K, Rick J, Xie SX, et al. Longitudinal study of normal cognition in Parkinson disease. Neurology. 2015;85(15):1276–82.

    Article  CAS  PubMed  Google Scholar 

  61. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.

    Article  PubMed  Google Scholar 

  62. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S1–5.

    Article  PubMed  Google Scholar 

  63. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745–8.

    Article  PubMed  Google Scholar 

  64. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509–18.

    Article  CAS  PubMed  Google Scholar 

  65. Olin JT, Aarsland D, Meng X. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dement Geriatr Cogn Disord. 2010;29(6):510–5.

    Article  CAS  PubMed  Google Scholar 

  66. Schmitt FA, Farlow MR, Meng X, et al. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther. 2010;16(6):330–6.

    Article  CAS  PubMed  Google Scholar 

  67. Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37(1):9–16.

    CAS  PubMed  Google Scholar 

  68. Mamikonyan E, Xie SX, Melvin E, et al. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30(7):912–8.

    Article  CAS  PubMed  Google Scholar 

  69. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230–8.

    Article  CAS  PubMed  Google Scholar 

  70. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: arandomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004;19(1):1–8.

    Article  PubMed  Google Scholar 

  73. Muller T, Welnic J, Fuchs G, et al. The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl. 2006;71:27–30.

    Article  PubMed  Google Scholar 

  74. Rowan E, McKeith IG, Saxby BK, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23(3):161–7.

    Article  CAS  PubMed  Google Scholar 

  75. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005;20(10):938–44.

    Article  PubMed  Google Scholar 

  76. Litvinenko IV, Odinak MM, Mogil'naya VI, et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol. 2008;38(9):937–45.

    Article  CAS  PubMed  Google Scholar 

  77. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18(10):937–41.

    Article  CAS  PubMed  Google Scholar 

  78. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  79. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson'sdisease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.

    Article  CAS  PubMed  Google Scholar 

  80. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.

    Article  CAS  PubMed  Google Scholar 

  81. Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord. 2009;24(8):1217–21.

    Article  PubMed  Google Scholar 

  82. Wesnes KA, Aarsland D, Ballard C, et al. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30(1):46–54.

    Article  PubMed  Google Scholar 

  83. Leroi I, Atkinson R, Overshott R. Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2014;29(9):899–905.

    Article  PubMed  Google Scholar 

  84. Larsson V, Engedal K, Aarsland D, et al. Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2011;32(4):227–34.

    Article  CAS  PubMed  Google Scholar 

  85. Stubendorff K, Larsson V, Ballard C, et al. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011;26(10):1851–8.

    Article  PubMed  Google Scholar 

  87. Marsh L, Biglan K, Gerstenhaber M, et al. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord. 2009;24(2):277–82.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010;289(1–2):12–7.

    Article  PubMed  Google Scholar 

  89. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–9.

    Article  PubMed  Google Scholar 

  90. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528–36.

    Article  CAS  PubMed  Google Scholar 

  91. Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, et al., Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45–52.

    Article  PubMed  Google Scholar 

  92. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66(1):93–8.

    Article  PubMed  Google Scholar 

  93. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67(4):416–21.

    Article  PubMed  Google Scholar 

  95. Oh YS, Kim JS, Lee PH. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson's Disease Dementia. J Mov Disord. 2015;8(2):98–102.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002;18(5):258–64.

    Article  CAS  PubMed  Google Scholar 

  97. Sobow T. Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol. 2007;41(3):276–9.

    PubMed  Google Scholar 

  98. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci. 2002;23(1):41–3.

    Article  CAS  PubMed  Google Scholar 

  99. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol. 2003;16(3):184–8.

    Article  PubMed  Google Scholar 

  100. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1999. 340(10): p. 757–63.

  101. Factor SA, Friedman JH, Lannon MC, et al. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001;16(1):135–9.

    Article  CAS  PubMed  Google Scholar 

  102. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry. 2004;161(9):1620–5.

    Article  PubMed  Google Scholar 

  104. Dewey Jr RB. and P.E. O'Suilleabhain, Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology. 2000;55(11):1753–4.

    Article  PubMed  Google Scholar 

  105. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 1999;14(3):484–7.

    Article  CAS  PubMed  Google Scholar 

  106. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol. 2000;20(1):54–60.

    Article  CAS  PubMed  Google Scholar 

  107. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119(12):2196–205.

    Article  CAS  PubMed  Google Scholar 

  108. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005;20(8):958–63.

    Article  PubMed  Google Scholar 

  109. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007;22(3):313–8.

    Article  PubMed  Google Scholar 

  110. Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:327–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–63.

    Article  CAS  PubMed  Google Scholar 

  112. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27(4):153–6.

    Article  CAS  PubMed  Google Scholar 

  113. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006;29(6):331–7.

    Article  CAS  PubMed  Google Scholar 

  114. Pintor L, Valldeoriola F, Bailles E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35(2):61–6.

    Article  CAS  PubMed  Google Scholar 

  115. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005;28(3):111–4.

    Article  CAS  PubMed  Google Scholar 

  116. Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007;109(2):188–91.

    Article  PubMed  Google Scholar 

  117. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002;52(5):438–45.

    Article  CAS  PubMed  Google Scholar 

  118. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55(6):789–94.

    Article  CAS  PubMed  Google Scholar 

  119. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031–5.

    Article  PubMed  Google Scholar 

  120. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord. 2002;17(1):221–2.

    Article  PubMed  Google Scholar 

  121. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27(1):4–5.

    Article  CAS  PubMed  Google Scholar 

  122. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006;21(12):2078–81.

    Article  PubMed  Google Scholar 

  123. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord. 2006;21(9):1538–9.

    Article  PubMed  Google Scholar 

  124. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40. This study demonstrates efficacy of a novel agent for treating psychosis in Parkinson's disease, without dopamine blockade or worsening of motor symptoms.

    Article  CAS  PubMed  Google Scholar 

  125. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. 2010;35(4):881–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015;30(2):121–7. This manuscript reviews the range of symptoms comprising impulse control disorders, including pathological gambling, buying, sexual behaviors, and dopamine dysregulation syndrome.

    Article  CAS  PubMed  Google Scholar 

  127. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.

    Article  PubMed  Google Scholar 

  128. Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord. 2013;28(3):327–33.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Hassan A, Bower JH, Kumar N, et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17(4):260–4.

    Article  CAS  PubMed  Google Scholar 

  130. Ceravolo R, Frosini D, Rossi C, et al. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15 Suppl 4:S111–5.

    Article  PubMed  Google Scholar 

  131. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–4.

    Article  PubMed  Google Scholar 

  132. Vitale C, Santangelo G, Erro R, et al. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord. 2013;19(4):483–4.

    Article  PubMed  Google Scholar 

  133. Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400–4.

    Article  PubMed  Google Scholar 

  134. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.

    Article  PubMed  Google Scholar 

  135. Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84(2):130–5.

    Article  PubMed  Google Scholar 

  136. Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83(9):826–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Liang JW, Shanker VL, Groves M. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2015;84(13):1386–7.

    Article  PubMed  Google Scholar 

  138. Rotondo A, Bosco D, Plastino M, et al. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord. 2010;25(12):1994–5.

    Article  PubMed  Google Scholar 

  139. Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol. 2007;27(1):107–8.

    Article  PubMed  Google Scholar 

  140. Hardwick A, Ward H, Hassan A, et al. Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease. Neurocase. 2013;19(6):587–91.

    Article  CAS  PubMed  Google Scholar 

  141. Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(5):448–9.

    Article  PubMed  Google Scholar 

  142. Kim YE, Kim HJ, Kim HJ, et al. Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. J Clin Neurosci. 2013;20(7):964–9.

    Article  PubMed  Google Scholar 

  143. Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain. 2012;135(Pt 5):1463–77.

    Article  PubMed  Google Scholar 

  144. Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One. 2012;7(1):e29768.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Amami P, Dekker I, Piacentini S, et al. Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86(5):562–4.

    Article  CAS  PubMed  Google Scholar 

  146. Broen M, Duits A, Visser-Vandewalle V, et al. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord. 2011;17(6):413–7.

    Article  PubMed  Google Scholar 

  147. Catalan MJ, de Pablo-Fernandez E, Villanueva C, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Mov Disord. 2013;28(14):2007–10.

    Article  CAS  PubMed  Google Scholar 

  148. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005;20(1):77–81.

    Article  PubMed  Google Scholar 

  149. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 2005;65(10):1570–4.

    Article  CAS  PubMed  Google Scholar 

  150. Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014;85(3):311–8.

    Article  PubMed  Google Scholar 

  151. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19(4):397–405.

    Article  PubMed  Google Scholar 

  152. O'Sullivan SS, Djamshidian A, Evans AH, et al. Excessive hoarding in Parkinson's disease. Mov Disord. 2010;25(8):1026–33.

    Article  PubMed  Google Scholar 

  153. Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Mov Disord. 2015;30(2):150–9. This review provides a critical assessment of management options for impulse control disorders in PD.

    Article  PubMed  Google Scholar 

  154. Salomone G, Marano M, di Biase L, et al. Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication. Parkinsonism Relat Disord. 2015;21(9):1124–5.

    Article  PubMed  Google Scholar 

  155. Solla P, Cannas A, Marrosu MG et al. Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel. Parkinsonism Relat Disord. 2015;21(11):1383--4.

  156. Sriram A, Ward HE, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol. 2013;260(2):521–7.

    Article  CAS  PubMed  Google Scholar 

  157. Epstein J, Madiedo CJ, Lai L, et al. Successful treatment of dopamine dysregulation syndrome with valproic acid. J Neuropsychiatry Clin Neurosci. 2014;26(3):E3.

    Article  PubMed  Google Scholar 

  158. Fasano A, Ricciardi L, Pettorruso M, et al. Management of punding in Parkinson's disease: an open-label prospective study. J Neurol. 2011;258(4):656–60.

    Article  CAS  PubMed  Google Scholar 

  159. Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease-observation in a patient. Mov Disord. 2008;23(1):129–30.

    Article  PubMed  Google Scholar 

  160. Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80(9):792–9.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013;84(8):868–74.

    Article  PubMed  Google Scholar 

  162. Okun MS, Weintraub D. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? Mov Disord. 2013;28(14):1915–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University School of Medicine, 932 Morreene Rd., Durham, NC, 27705, USA

    Jeffrey W. Cooney

  2. Duke University School of Medicine, 120a Davison, Durham, NC, 27705, USA

    Mark Stacy

Authors
  1. Jeffrey W. Cooney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Stacy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Stacy.

Ethics declarations

Conflict of Interest

Jeffrey W. Cooney declares that he has no conflict of interest.

Mark Stacy works for Duke University, and has received consultancy fees from Eli Lilly, Merz, Osmotica, Pfizer, SK Life Sciences, Allergan, Avid, Best Doctors, Biotie, Lundbeck, Neuronova, Novartis Pharma (Japan), Saraepta Therapeutics, and Sunovion Pharmaceutics, Inc. Dr. Stacy has also received grants from the Michael J. Fox Foundation, the NIH, the Parkinson Study Group, and Pharma 2B, royalties from Informa Press for the Handbook of Dystonia and Duke University for the Wearing Off Questionnaire. He has also recieved payment for development of educational presentations from the University of Kansas, the University of Miami, and the University of Rochester. Dr. Stacy also received paid travel accommodations from the Cleveland Clinic Neurological Institute, the Movement Disorder Society, and the National Parkinson Foundation.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Movement Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cooney, J.W., Stacy, M. Neuropsychiatric Issues in Parkinson’s Disease. Curr Neurol Neurosci Rep 16, 49 (2016). https://doi.org/10.1007/s11910-016-0647-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-016-0647-4

Keywords

Search

Navigation